Célèste Lebbé

89.2k total citations · 9 hit papers
543 papers, 18.0k citations indexed

About

Célèste Lebbé is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Célèste Lebbé has authored 543 papers receiving a total of 18.0k indexed citations (citations by other indexed papers that have themselves been cited), including 374 papers in Oncology, 192 papers in Molecular Biology and 103 papers in Immunology. Recurrent topics in Célèste Lebbé's work include Melanoma and MAPK Pathways (136 papers), Cancer Immunotherapy and Biomarkers (117 papers) and CAR-T cell therapy research (114 papers). Célèste Lebbé is often cited by papers focused on Melanoma and MAPK Pathways (136 papers), Cancer Immunotherapy and Biomarkers (117 papers) and CAR-T cell therapy research (114 papers). Célèste Lebbé collaborates with scholars based in France, United States and Italy. Célèste Lebbé's co-authors include Omid Hamid, Jeffrey S. Weber, Jedd D. Wolchok, Axel Hoos, Steven O’Day, Michele Maio, F. Stephen Hodi, Jean‐Jacques Grob, Rachel Humphrey and Michael Binder and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Célèste Lebbé

505 papers receiving 17.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

2009 2.3k citations Jedd D. Wolchok, Axel Hoos et al. Clinical Cancer Research profile →
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

2009 934 citations Jedd D. Wolchok, Bart Neyns et al. profile →
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

2016 933 citations Omid Hamid, Shailender Bhatia et al. profile →
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

2017 482 citations Philippe Saïag, Caroline Robert et al. profile →
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

2017 471 citations Omid Hamid, Claus Garbe et al. Journal of Clinical Oncology profile →
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

2017 397 citations Célèste Lebbé et al. European Journal of Cancer profile →
Merkel cell carcinoma

2017 377 citations Célèste Lebbé, Paul Nghiem et al. profile →
Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline

2015 371 citations Célèste Lebbé, Jean‐Jacques Grob et al. European Journal of Cancer profile →
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

2015 340 citations Claus Garbe, Célèste Lebbé et al. European Journal of Cancer profile →

Peers

Countries citing papers authored by Célèste Lebbé

Since Specialization

Citations

This map shows the geographic impact of Célèste Lebbé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Célèste Lebbé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Célèste Lebbé more than expected).

Fields of papers citing papers by Célèste Lebbé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Célèste Lebbé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Célèste Lebbé. The network helps show where Célèste Lebbé may publish in the future.

Co-authorship network of co-authors of Célèste Lebbé

This figure shows the co-authorship network connecting the top 25 collaborators of Célèste Lebbé. A scholar is included among the top collaborators of Célèste Lebbé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Célèste Lebbé. Célèste Lebbé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma 2025 ·EMBO Molecular Medicine ·(unknown), Nadine Benhamouda, Lucie Biard, Laetitia Da Meda, Kristell Desseaux, (unknown), (unknown), (unknown), Aurélie Sadoux, (unknown), Jean‐François Deleuze, (unknown), Yimin Shen, Matthieu Resche‐Rigon, Samia Mourah, Célèste Lebbé, Éric Tartour	2
2	Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight‐adjusted dose, a multicenter observational study 2024 ·Cancer ·(unknown), Stéphane Dalle, Laurent Mortier, O. Dereure, (unknown), Caroline Dutriaux, M.‐T. Leccia, Délphine Legoupil, Henri Montaudié, Julie De Quatrebarbes, Caroline Gaudy‐Marqueste, E. Maubec, Philippe Saïag, Cécile Pagès, (unknown), F. Granel‐Brocard, Raphaël Porcher, (unknown), Célèste Lebbé, Emmanuelle Kempf	2
3	Continuous intrathecal infusion of nivolumab in advanced melanoma with leptomeningeal disease. 2024 ·Journal of Clinical Oncology ·(unknown), Lauriane Goldwirt, Fanélie Jouenne, N. Kramkimel, Barouyr Baroudjian, (unknown), F. Nataf, (unknown), (unknown), (unknown), S. Aractingi, Stéphane Goutagny, Samia Mourah, Célèste Lebbé, Philippe Decq	0
4	PROM2 overexpression induces metastatic potential through epithelial‐to‐mesenchymal transition and ferroptosis resistance in human cancers 2024 ·Clinical and Translational Medicine ·(unknown), Claire Wilhelm, Célèste Lebbé, Mohammed I. Y. Elmallah, Frédéric Pamoukdjian, (unknown), Guillaume Gapihan, Aurore Van de Walle, (unknown), (unknown), Clara Allayous, Maxime Battistella, E. Van Glabeke, Kah Wai Lim, Christophe Lebœuf, Sébastien Roger, Géraldine Falgarone, Anh Tuân Phan, Guilhem Bousquet	10
5	When to stop immunotherapy for advanced melanoma: Emulation of target trials. 2024 ·Journal of Clinical Oncology ·(unknown), Laurent Mortier, Stéphane Dalle, O. Dereure, S. Dalac, Caroline Dutriaux, M.‐T. Leccia, E. Maubec, Jean‐Philippe Arnault, F. Brunet‐Possenti, Julie De Quatrebarbes, (unknown), Caroline Gaudy‐Marqueste, Cécile Pagès, Pierre‐Emmanuel Stoebner, Délphine Legoupil, Henri Montaudié, (unknown), Célèste Lebbé, Raphaël Porcher	0
6	Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study. 2024 ·Journal of Clinical Oncology ·Reinhard Dummer, Jean‐Jacques Grob, Caroline Robert, Ronnie Shapira‐Frommer, Célèste Lebbé, Paolo A. Ascierto, Stéphane Dalle, Omid Hamid, Nicolás Meyer, Muhammad Adnan Khattak, Andrew Hill, Jonathan Cohen, Giuseppe Curigliano, Anna Maria Di Giacomo, Michele Del Vecchio, Sekwon Jang, (unknown), Xuan Peng, Scott J. Diede, Georgina V. Long	2
7	Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Alexander M. Menzies, (unknown), Robyn P.M. Saw, Winan J. van Houdt, Mark B. Faries, Caroline Robert, Paolo A. Ascierto, Célèste Lebbé, Matteo S. Carlino, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, (unknown), Georgina V. Long, Christian U. Blank, Lonneke V. van de Poll‐Franse, J. Lijnsvelt	0
8	1146P Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC) 2023 ·Annals of Oncology ·Giovanni Grignani, Piotr Rutkowski, Célèste Lebbé, Michele Guida, (unknown), Filippo de Braud, Francesco Spagnolo, Melissa Burgess, Henri Montaudié, Roberta Depenni, Francesca Spada, (unknown), Mark Cornfeld, Chuan Tian, Shailender Bhatia	10
9	1140P Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA 2023 ·Annals of Oncology ·E. Gérard, Célèste Lebbé, Émilie Lanoy, G. Quéreux, Philippe Bernard, (unknown), Nicolás Meyer, Laurent Mortier, (unknown), Délphine Legoupil, Eve‐Marie Neidhardt, Philippe Saïag, (unknown), P. Celérier, Charlée Nardin, E. Maubec, (unknown), Stéphanie Perrier, (unknown), Caroline Robert	3
10	Unmasking the tumourigenic role of SIN1/MAPKAP1 in the mTOR complex 2 2023 ·Clinical and Translational Medicine ·(unknown), Célèste Lebbé, Nicolas Dumaz	6
11	Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1 2022 ·Clinical Cancer Research ·Caroline Robert, Célèste Lebbé, Thierry Lesimple, (unknown), (unknown), (unknown), (unknown), Barouyr Baroudjian, Émilie Routier, Ferdy J. Lejeune	15
12	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study 2021 ·Journal for ImmunoTherapy of Cancer ·Sandra P. D’Angelo, Célèste Lebbé, Laurent Mortier, Andrew S. Brohl, Nicola Fazio, Jean‐Jacques Grob, Natalie Prinzi, Glenn J. Hanna, Jessica C. Hassel, Felix Kiecker, (unknown), Barbara Ellers‐Lenz, Parantu K. Shah, (unknown), Paul Nghiem	80
13	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination 2020 ·International Journal of Cancer ·Éléonore De Guillebon, (unknown), Antonin Saldmann, Sylvie Séguier, Thi Tran, Léa Paolini, Célèste Lebbé, Éric Tartour	47
14	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover 2020 ·Cancers ·Célèste Lebbé, Caroline Dutriaux, Thierry Lesimple, (unknown), Joseph Kerger, L. Thomas, B. Guillot, Filippo de Braud, Claus Garbe, Jean‐Jacques Grob, Carmen Loquai, Virginia Ferraresi, Caroline Robert, P. Vasey, Robert M. Conry, Richard Isaacs, Enrique Espinosa, Armin Schueler, (unknown), Brigitte Dréno	32
15	Netrin-1 and Its Receptor DCC Are Causally Implicated in Melanoma Progression 2019 ·Cancer Research ·Amina Boussouar, (unknown), (unknown), Andréa Paradisi, Nicolas Gadot, (unknown), David Neves, Lionel Larue, Maxime Battistella, Christophe Lebœuf, Célèste Lebbé, Anne Janin, Patrick Mehlen	19
16	Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma 2019 ·Current Opinion in Oncology ·Julie Delyon, Célèste Lebbé, Nicolas Dumaz	26
17	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial 2019 ·European Journal of Cancer ·Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Fareeda Hosein, Veerle de Pril, Michal Kiciński, Stefan Suciu, Alessandro Testori	123
18	Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma 2013 ·Journal of Clinical Oncology ·Paolo A. Ascierto, David R. Minor, Antoni Ribas, Célèste Lebbé, Anne O’Hagan, Niki Arya, Mary Guckert, Dirk Schadendorf, Richard Kefford, Jean‐Jacques Grob, Omid Hamid, Ravi K. Amaravadi, Ester Simeone, Tabea Wilhelm, Kevin B. Kim, Georgina V. Long, Anne-Marie Martin, Jolly Mazumdar, Vicki Goodman, Uwe Trefzer	338
19	Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients 2010 ·Clinical Cancer Research ·Delphine Kérob, Raphaël Porcher, O Vérola, Stéphane Dalle, E. Maubec, F. Aubin, M. D’Incan, (unknown), S. Boulinguez, Isabelle Madelaine‐Chambrin, A. Mathieu-Boué, Jean-Marie Servant, É. de Kerviler, Anne Janin, Fabien Calvo, Florence Pédeutour, Célèste Lebbé	98
20	EFFECT OF DOSE ON EFFICACY AND SAFETY IN IPILIMUMAB-TREATED PATIENTS WITH ADVANCED MELANOMA - RESULTS FROM A PHASE II, RANDOMIZED, DOSE-RANGING STUDY 2008 ·Annals of Oncology ·Célèste Lebbé, Axel Hoos, Kevin M. Chin, (unknown), Bart Neyns, Gerald P. Linette, Sylvie Négrier, Dirk Schadendorf, Michael Smylie, (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact